Cookie Consent by Free Privacy Policy Generator Update cookies preferences

Session 36

OESO-SEMPIRE 16th World Conference | Esophagus 2024 | Strasbourg | April 23-26, 2024 | Venue: IRCAD France

<  back to Program at a glance
<  back to all the scientific sessions

 

Session 36: Pathology 2

Friday, April 26, 4:00 – 5:30 pm
Auditorium Lindbergh

Esophageal carcinoma​
Chairs: Dhanpat Jain (USA) – Rupert Langer (France)

  1. Should we routinely test for DNA-MMR/MSI esophageal carcinoma (SCC/Adenocarcinoma) – Florence Renaud (France)
  2. Should we routinely test for SMARC4/INI in esophageal carcinomas – Monika Tripathi (Canada)
  3. Should we test for PDL-1 in esopageal carcinoma (SCC/Adenoca) and how to report PDL-1 – Paul E. Swanson (USA)
  4. What is the status of claudin 18.2 testing in esophageal carcinoma – Dhanpat Jain (USA)
  5. What are the next diagnostic/prognostic and therapeutic biomarkers for esophageal carcinoma after claudin 18.2 and PD-L1? – Florence Renaud (France)
  6. Any role of reporting "Her2 low" in GEJ adenocarcinoma – Maha Guindi (USA)
  7. What is the role of NGS in esophageal carcinoma? – Rupert Langer (Austria)
  8. What is upcoming and novel biomarkers for progression in BE and dysplasia? – Catherine J. Streutker (Canada)
  9. What is the current status of AI and ML application in the pathologic diagnosis of esophageal carcinoma – Bastian Dislich (Switzerland)
  10. What is the current status of AI and ML application in assesment of tumor regression post neo-adjuvant treated esophageal carcinoma – Deyali Chatterjee (USA)
  11. What is the role of liquid biopsy in esophageal carcinoma? – Bastian Dislich (Switzerland)
    Q&A